Grace Therapeutics Reports $7.8M Net Loss for FY26, Auditors Doubt Going Concern
GRCE sits 26% above its 52-week low of $1.79 on light trading volume (0.2× avg).
Summary
Grace Therapeutics reported a net loss of $(7.8)M for fiscal year 2026, with diluted EPS of $(0.47). While this represents an improvement from the $(9.6)M loss in FY25, the reduction is primarily due to a $7.1M decrease in R&D spending as the company wound down its lead drug program. This financial update follows the 10-K filing minutes earlier, which disclosed major operational and financial challenges, including the FDA's rejection of its lead drug and auditors expressing substantial doubt about the company's ability to continue as a going concern. The results underscore the severe financial strain and uncertain future for the company, which plans additional capital raises.
At the time of this announcement, GRCE was trading at $2.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.4M. The 52-week trading range was $1.79 to $5.18. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.